572 related articles for article (PubMed ID: 25741004)
41. Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains.
Diallo JS; Vähä-Koskela M; Le Boeuf F; Bell J
Methods Mol Biol; 2012; 797():127-40. PubMed ID: 21948474
[TBL] [Abstract][Full Text] [Related]
42. [Vesicular stomatitis virus in the fight against cancer].
Janelle V; Poliquin L; Lamarre A
Med Sci (Paris); 2013 Feb; 29(2):175-82. PubMed ID: 23452604
[TBL] [Abstract][Full Text] [Related]
43. Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
Wollmann G; Paglino JC; Maloney PR; Ahmadi SA; van den Pol AN
Virology; 2015 Jan; 475():1-14. PubMed ID: 25462341
[TBL] [Abstract][Full Text] [Related]
44. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
Hastie E; Grdzelishvili VZ
J Gen Virol; 2012 Dec; 93(Pt 12):2529-2545. PubMed ID: 23052398
[TBL] [Abstract][Full Text] [Related]
45. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
46. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
[TBL] [Abstract][Full Text] [Related]
47. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
[TBL] [Abstract][Full Text] [Related]
48. Vesiculovirus neutralization by natural IgM and complement.
Tesfay MZ; Ammayappan A; Federspiel MJ; Barber GN; Stojdl D; Peng KW; Russell SJ
J Virol; 2014 Jun; 88(11):6148-57. PubMed ID: 24648451
[TBL] [Abstract][Full Text] [Related]
49. Vesicular stomatitis virus as a treatment for colorectal cancer.
Stewart JH; Ahmed M; Northrup SA; Willingham M; Lyles DS
Cancer Gene Ther; 2011 Dec; 18(12):837-49. PubMed ID: 21886191
[TBL] [Abstract][Full Text] [Related]
50. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
Wu L; Huang TG; Meseck M; Altomonte J; Ebert O; Shinozaki K; García-Sastre A; Fallon J; Mandeli J; Woo SL
Hum Gene Ther; 2008 Jun; 19(6):635-47. PubMed ID: 18533893
[TBL] [Abstract][Full Text] [Related]
51. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
[TBL] [Abstract][Full Text] [Related]
52. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
53. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D
Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872
[TBL] [Abstract][Full Text] [Related]
54. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
55. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
56. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
Zhang P; Han X; Tan W; Chen D; Sun Q
Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
[TBL] [Abstract][Full Text] [Related]
57. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
van den Pol AN; Mao G; Chattopadhyay A; Rose JK; Davis JN
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077641
[TBL] [Abstract][Full Text] [Related]
58. Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis.
AuYeung AWK; Mould RC; Stegelmeier AA; van Vloten JP; Karimi K; Woods JP; Petrik JJ; Wood GA; Bridle BW
Sci Rep; 2021 Jul; 11(1):15290. PubMed ID: 34315959
[TBL] [Abstract][Full Text] [Related]
59. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
[TBL] [Abstract][Full Text] [Related]
60. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D
Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]